Idorsia Pharmaceuticals US Inc.
One Radnor Corporate Center
100 Matsonford Road, Suite 101
About Idorsia Pharmaceuticals US Inc.
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas; we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland, the US Commercial Operations & Clinical Development teams are based near Philadelphia, Pennsylvania. Idorsia is committed to meet the changing needs of healthcare professionals, patients and their families. The core of what we do is to bring creative solutions to the market based on our science and data.
Company Ownership: Public
Stock Symbol: IDIA
Stock Exchange: SIX Swiss Exchange
16 articles with Idorsia Pharmaceuticals US Inc.
Idorsia Ltd announced its financial results for the first half of 2022.
Idorsia Announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as Patient Ambassador for QUVIVIQ™ (daridorexant), a Once Nightly Treatment for Insomnia
Idorsia Pharmaceuticals, U.S. Inc, today announced its partnership with Lindsey Vonn, world champion skier, philanthropist, entrepreneur and insomnia patient as an ambassador for QUVIVIQ™ (daridorexant) CIV.
SLEEP 2022: Idorsia U.S. to present data from Wake Up America survey, revealing the hidden toll of insomnia, along with three other abstracts on the evaluation and treatment of insomnia
Idorsia Pharmaceuticals, U.S. Inc., announced that results from the Wake Up America survey, conducted by The Alliance for Sleep and sponsored by Idorsia, will be presented at SLEEP 2022, the 36th annual congress hosted by the Associated Professional Sleep Societies.
Several biopharma companies are opening the week with positive clinical trial news. Read on for updates from Cytokinetics, Concert Pharmaceuticals, Idorsia and Seagen.
Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ (daridorexant) through Partnership with Pharmacy Services Provider
Following the launch of QUVIVIQ™ CIV on May 2, Idorsia Pharmaceuticals, U.S. Inc. announced that the first wave of patients has been prescribed the product through a pharmacy services provider.
Idorsia is no longer continuing research into the use of ACT-539313 to treat binge eating disorders after failing to meet the primary endpoint in its latest trial.
Idorsia's new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
Idorsia Ltd (SIX: IDIA) & Idorsia Pharmaceuticals, US Inc. today announced that QUVIVIQ™ (daridorexant) CIV 25 mg and 50 mg tablets are now commercially available for adult patients with insomnia, which is characterized by trouble with falling or staying asleep.
Idorsia Ltd and Idorsia Pharmaceuticals Japan announced that PIVLAZ™ is now available to physicians in Japan to start treating aSAH patients.
Results Announced from Largest U.S. Survey of People with Trouble Sleeping, as well as Doctors, to Better Understand the Hidden Toll of Insomnia
The Alliance for Sleep today announced eye-opening results from its landmark survey, Wake Up America: The Night & Day Impact of Insomnia, conducted online by The Harris Poll.
Veeva Systems (NYSE: VEEV) today announced that Idorsia Pharmaceuticals Ltd (SIX: IDIA) has expanded its use of Veeva Vault Clinical Suite applications to include Veeva Vault CDMS for electronic data capture (EDC) and coding.
Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025
QUVIVIQ™ (daridorexant) 25 mg and 50 mg approved by the US Food and Drug Administration (FDA) for the treatment of adults with insomnia.
Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada
Idorsia Ltd and Syneos Health® announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada.
The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
As reported in the Lancet Neurology, daridorexant is the first insomnia medication to demonstrate an effect of a drug therapy to improve both nighttime symptoms and daytime functioning.
Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
Allschwil, Switzerland– January10, 2022 Idorsia Ltd announced that the US Food and Drug Administration has approved QUVIVIQ™ 25 mg and 50 mg for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance1.
The approval was based on data from a broad clinical program of 1,854 adults with insomnia conducted at more than 160 clinical sites in 18 countries.
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.